Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients

INTRODUCTION: To prove the feasibility and safety of a conversion to once-daily injected GLP1 agonist (lixisenatide) and long-acting basal insulin analogue (glargine) in patients with T2DM and poorly controlled glycemia previously treated with multiple injections of premixed insulins (iPremix) in an...

Descripción completa

Detalles Bibliográficos
Autores principales: Harreiter, Jürgen, Kosi-Trebotic, Lana, Lukas, Albert, Wolf, Peter, Winhofer, Yvonne, Luger, Anton, Kautzky-Willer, Alexandra, Krebs, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446376/
https://www.ncbi.nlm.nih.gov/pubmed/28357772
http://dx.doi.org/10.1007/s13300-017-0249-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446376/
https://www.ncbi.nlm.nih.gov/pubmed/28357772
http://dx.doi.org/10.1007/s13300-017-0249-4

Ejemplares similares